SEC Info - Acer Therapeutics Inc. - ‘8-K’ for 8/23/22

SEC Info℠

Home

Help

Please Sign In

Acer Therapeutics Inc. – ‘8-K’ for 8/23/22

On: Tuesday, 8/23/22, at 4:04pm ET · For: 8/23/22 · Accession #: 1564590-22-29967 · File #: 1-33004

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/23/22  Acer Therapeutics Inc.            8-K:7,9     8/23/22   11:8M                                     ActiveDisclosure/FA

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     41K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     44K 
 6: R1          Document and Entity Information                     HTML     49K 
 9: XML         IDEA XML File -- Filing Summary                      XML     12K 
 7: XML         XBRL Instance -- acer-8k_20220823_htm                XML     15K 
 8: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 4: EX-101.LAB  XBRL Labels -- acer-20220823_lab                     XML     60K 
 5: EX-101.PRE  XBRL Presentations -- acer-20220823_pre              XML     36K 
 3: EX-101.SCH  XBRL Schema -- acer-20220823                         XSD     18K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    19K 
11: ZIP         XBRL Zipped Folder -- 0001564590-22-029967-xbrl      Zip     33K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C: C: C: C: C:

i false i 0001069308 0001069308 2022-08-23 2022-08-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): i August 23, 2022

i ACER THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

i Delaware		i 001-33004		i 32-0426967
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

i One Gateway Center, i Suite 356 i 300 Washington Street i Newton, i Massachusetts		i 02458
(Address of principal executive offices)		(Zip Code)
Registrant’s telephone number, including area code: ( i 844) i 902-6100
N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

i ☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i ☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i ☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i ☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
i Common Stock, $0.0001 par value per share	i ACER	i The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01.Regulation FD Disclosure.

Acer Therapeutics Inc. (the “Company”) has updated its Corporate Presentation that will be available on the Investor Relations page of the Company’s website at https://acertx.com/investor-relations and will be used at investor and other meetings. A copy of the updated Corporate Presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Company does not undertake to update this presentation except as required by law.

The information in Item 7.01 of this Current Report on Form 8-K, including exhibit 99.1 shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01.Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.		Description


99.1		Acer Therapeutics Inc. Corporate Presentation, August 23, 2022.

104		Cover page interactive data file (embedded within the inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: August 23, 2022	ACER THERAPEUTICS INC.

	By:	/s/ *Harry S. Palmin*
		Harry S. Palmin
		Chief Financial Officer

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on / For Period end:	8/23/22	8-K
		List all Filings

1 Previous Filing that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/07/22  Acer Therapeutics Inc.            8-K:1,2,3,7 3/04/22   19:2.1M                                   Donnelley … Solutions/FA

↑Top

Filing Submission 0001564590-22-029967 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)